Stephanie Lankhorst et al.
Hypertension (Dallas, Tex. : 1979), 66(3), 543-549 (2015-07-22)
Hypertension and renal injury are off-target effects of sunitinib, a tyrosine kinase receptor inhibitor used for the treatment of various tumor types. Importantly, these untoward effects are accompanied by activation of the endothelin system. Here, we set up a study